sglt2 inhibitors and glp 1 receptor agonists GLP-1 in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Effect of combination treatment with
Description
By 24 months, the proportion of patients with ongoing papilledema was lower in the tirzepatide group (RR 0.32, 95% CI 0.1890.542)
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
This framework offers a structured way to evaluate how emerging therapies may influence biological aging
(2020) 5:e133429
And in August, Pfizer ended development of its third and final oral GLP-1 candidate, PF-06954522, after a review of its phase 1 clinical performance and the overall GLP-1 landscape
